MedTrace Logo

Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)

NCT01189526 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-08-26

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy of intravitreal Ranibizumab in comparison with macular laser photocoagulation as treatments for macular edema secondary to branch retinal vein occlusion.

Characteristics of this study is as below

1. Multicenter, randomized clinical trial. (intravitreal Ranibizumab 0.5mg injection vs. macular laser photocoagulation)
2. After 48 weeks follow up, functional change(visual acuity)and anatomical change (central retinal thickness) would be evaluated

Conditions

  • Branch Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab

Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.

PROCEDURE

macular laser photocoagulation

Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Seoul Retina Investigator Group

    lead NETWORK

Principal Investigators

  • Se Woong Kang, M.D. · Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine

  • Jae Pil Shin, M.D. · Department of Ophthalmology, Kyungpook National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-08-31
Completion
2011-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189526 on ClinicalTrials.gov